Absci Corp (ABSI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$9.7M
Cash & Equivalents
$26.3M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$1,796M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07317544 | Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia | PHASE2 | Recruiting | 227 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-24 | 8-K | Absci Corp (ABSI) (CIK 0001672688) - EX-99.1 | EDGAR |